Initial Statement of Beneficial Ownership (3)
March 05 2015 - 12:55PM
Edgar (US Regulatory)
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Berge Terence M
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/25/2015
|
3. Issuer Name
and
Ticker or Trading Symbol
CONMED CORP [CNMD]
|
|
(Last)
(First)
(Middle)
C/O CONMED CORPORATION, 525 FRENCH ROAD
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
VP Corp. Treasurer /
|
|
(Street)
UTICA, NY 13502
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
|
401 (K) Plan
|
1231.172
|
I
|
401 (K) Plan
(1)
|
|
Common Stock
|
10531
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
|
Rsus (restricted Stock Units)
|
(2)
|
6/1/2020
|
Common Stock
|
800
|
$0
|
D
|
|
|
Rsus (restricted Stock Units)
|
(3)
|
6/1/2020
|
Common Stock
|
1760
|
$0
|
D
|
|
|
Rsus (restricted Stock Units)
|
(2)
|
6/1/2021
|
Common Stock
|
1600
|
$0
|
D
|
|
|
Rsus (restricted Stock Units)
|
(2)
|
6/1/2022
|
Common Stock
|
2400
|
$0
|
D
|
|
|
Rsus (restricted Stock Units)
|
(2)
|
6/1/2023
|
Common Stock
|
3200
|
$0
|
D
|
|
|
Rsus (restricted Stock Units)
|
(2)
|
6/1/2024
|
Common Stock
|
2600
|
$0
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(4)
|
5/17/2017
|
Common Stock
|
2500
|
$29.92
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(4)
|
6/1/2018
|
Common Stock
|
2500
|
$26.69
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(5)
|
6/1/2019
|
Common Stock
|
2000
|
$16.46
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(5)
|
6/1/2020
|
Common Stock
|
10000
|
$19.26
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(5)
|
6/1/2021
|
Common Stock
|
10000
|
$27.63
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(5)
|
6/1/2022
|
Common Stock
|
10000
|
$26.09
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(5)
|
6/1/2023
|
Common Stock
|
10000
|
$32.93
|
D
|
|
|
Sars (Stock Appreciation Rights)
|
(5)
|
6/1/2024
|
Common Stock
|
6500
|
$44.90
|
D
|
|
|
Explanation of Responses:
|
|
(
1)
|
The 1,231.172 represent shares equivalent in a Company stock fund in the 401 (K) Plan.
|
|
(
2)
|
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs generally vesting over a five year period with the first 20% of the RSU's vesting one year after the grant date.
|
|
(
3)
|
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs vesting over a seven year period with 14% of the RSU's vesting in the first through the fifth year after the grant date and 15% vesting in the sixth and seventh year.
|
|
(
4)
|
The stock appreciation rights ("SARs") were granted under the Company's 2006 Stock Incentive Plan and generally vest in equal amounts over a five year period.
|
|
(
5)
|
The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.
|
Reporting Owners
|
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Berge Terence M
C/O CONMED CORPORATION
525 FRENCH ROAD
UTICA, NY 13502
|
|
|
VP Corp. Treasurer
|
|
Signatures
|
|
/s/ Daniel S. Jonas for Terence M. Berge by Power of Attorney
|
|
3/5/2015
|
|
**
Signature of Reporting Person
|
Date
|
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Apr 2023 to Apr 2024
